Cyclerion Therapeutics (NASDAQ:KRSA) Stock Rated Buy in New Coverage at Guggenheim

Guggenheim initiated coverage on shares of Cyclerion Therapeutics (NASDAQ:KRSA) in a research note issued to investors on Monday, Marketbeat reports. The firm issued a buy rating and a $70.00 price target on the stock.

Several other equities analysts have also recently issued reports on KRSA. Zacks Research raised Cyclerion Therapeutics to a “hold” rating in a report on Wednesday, September 9th. Stifel Nicolaus started coverage on Cyclerion Therapeutics in a report on Monday, September 14th. They issued a “buy” rating and a $43.00 target price on the stock. TD Cowen initiated coverage on Cyclerion Therapeutics in a research report on Monday, September 14th. They issued a “buy” rating for the company. Finally, UBS Group initiated coverage on Cyclerion Therapeutics in a research note on Friday, September 11th. They set a “buy” rating and a $55.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Cyclerion Therapeutics has a consensus rating of “Buy” and a consensus price target of $56.00.

Cyclerion Therapeutics Trading Down 5.9%

Shares of NASDAQ:KRSA opened at $32.00 on Monday. Cyclerion Therapeutics has a 12 month low of $7.19 and a 12 month high of $59.36.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases with substantial unmet medical needs. The company was established in 2019 as a spinout from Ironwood Pharmaceuticals and built its research portfolio around soluble guanylate cyclase (sGC) stimulation, a mechanism involved in regulating blood flow and cellular signaling.

Cyclerion’s development programs included olinciguat, an investigational therapy studied in sickle cell disease and other vascular conditions; praliciguat, an sGC stimulator evaluated for cardiometabolic and renal diseases; and IW-6463, a central nervous system-penetrant sGC stimulator investigated for neurological disorders.